News Column

Singulex Appoints Peter Heseltine, M.B., B.Ch., B.A.O., as Chief Medical Officer

June 2, 2014



By a News Reporter-Staff News Editor at Clinical Trials Week -- Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, announced the appointment of Peter Heseltine, M.B., B.Ch., B.A.O., as Chief Medical Officer. At Singulex, Dr. Heseltine will have overall responsibility for clinical strategy, including scientific and medical affairs (see also Singulex, Inc.).

"Peter brings a wealth of experience to the Singulex team, particularly in terms of his medical experience with high-volume clinical laboratories, the management of in vitro diagnostic products and his success in developing various new diagnostics, including important new cancer diagnostics," said Guido Baechler, President and Chief Executive Officer at Singulex. "This background makes Peter an ideal fit for Singulex, as we continue to expand our roster of immunoassay solutions and testing services that enable a more proactive approach to disease detection and management."

"I am very impressed with Singulex's innovative single molecule counting technology and the company's approach to applying this cutting-edge technology to a variety of applications and diseases," said Dr. Heseltine. "I look forward to helping Singulex build upon the success they've achieved in their Life Science Products and Clinical Lab Testing businesses, and to contributing to the growth of their emerging Clinical Diagnostics business through the commercialization and clinical testing of the Sgx Clarity™ System for in vitro diagnostics."

Peter is a Fellow of the American College of Physicians, National Academy of Clinical Biochemistry, and Infectious Diseases Society of America, and maintains a position as Professor of Clinical Medicine at the University of California, Irvine. Nationally, he serves as Chairman, Data Safety Monitoring Board, Intramural Program on Addiction, National Institute of Drug Abuse, NIH, and is past Chairman of Division L, American Society for Microbiology. Prior to joining Singulex, Peter served as Senior Vice President and Chief Medical Officer at Prometheus Laboratories, where his responsibilities included overseeing clinical trials for oncology therapeutics and in vitro diagnostics validation trials. Previously, Peter held executive positions at Beckman Coulter and Quest Diagnostics Nichols Institute. He was a Professor of Medicine at the University of Southern California and Associate Chairman of Medicine at the Los Angeles County USC Medical Center, co-founding the Rand Schrader HIV/AIDS clinic. Peter has published and presented roughly one hundred peer-reviewed papers.

Peter received his medical training at Trinity College, Dublin University, and postgraduate training at Yale University, the University of California, Los Angeles, and at the U.S. Centers for Disease Control. He is Board certified in Internal Medicine and Infectious Diseases. About Singulex, Inc.Singulex is the developer and leading provider of single molecule counting (SMCTM) technology for clinical diagnostics and scientific discovery. Singulex's proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex's ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management, and fueling the discovery and development of new therapeutics.

Singulex provides SMC technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC technology. Singulex currently is developing the Sgx ClarityTM System, a fully-automated in vitro diagnostics system that will bring the benefits of its SMC technology to hospital and reference labs worldwide. For further information, please visit www.singulex.com.

Keywords for this news article include: Technology, Singulex Inc., Clinical Trials and Studies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters